Topical drug delivery devices: A review

Bertens, Christian J F; Gijs, Marlies; Biggelaar, Frank J H M van den; Nuijts, Rudy M.M.A.

doi:10.1016/j.exer.2018.01.010

Cited by 74 publications

(55 citation statements)

References 144 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These inserts are placed topically in the lower fornix and, less frequently, in the upper fornix or on the cornea. The initial discomfort upon administration is a disadvantage that arises from their solid state; other disadvantages include possible movement around the eye, occasional inadvertent loss during sleep or while rubbing the eyes, interference with vision, and generally difficult placement (and removal, for insoluble devices) [93,94]. Ocusert is a delicate, insoluble, and non-degradable reservoir device that is filled with sufficient pilocarpine for 1 week of use, whereas Lacrisert is a soluble mini rod of nonmedicated hydroxypropyl cellulose that dissolves within 24 h for the treatment of dry-eye syndromes [95].…”

Section: Inserts and Contact Lensesmentioning

confidence: 99%

Polysaccharides in Ocular Drug Delivery

et al. 2019

View full text Add to dashboard Cite

Polysaccharides, such as cellulose, hyaluronic acid, alginic acid, and chitosan, as well as polysaccharide derivatives, have been successfully used to augment drug delivery in the treatment of ocular pathologies. The properties of polysaccharides can be extensively modified to optimize ocular drug formulations and to obtain biocompatible and biodegradable drugs with improved bioavailability and tailored pharmacological effects. This review discusses the available polysaccharide choices for overcoming the difficulties associated with ocular drug delivery, and it explores the reasons for the dependence between the physicochemical properties of polysaccharide-based drug carriers and their efficiency in different formulations and applications. Polysaccharides will continue to be of great interest to researchers endeavoring to develop ophthalmic drugs with improved effectiveness and safety.

show abstract

Section: Inserts and Contact Lensesmentioning

confidence: 99%

Polysaccharides in Ocular Drug Delivery

et al. 2019

View full text Add to dashboard Cite

show abstract

“…63 However, previous studies have shown that non-compliance with eye drops is much higher than the average ophthalmologist may suspect. Studies investigating the compliance in glaucoma patients report self-reported non-adherence in 39.2% of patients, as opposed to an ophthalmologist-noticed non-compliance in only 2.1% of patients.…”

Section: Dropless Cataract Surgerymentioning

confidence: 83%

“…66 A high drug concentration in the tear film is required to achieve adequate intraocular concentrations, which often leads to ocular side effects. 63 These findings are only some of the many reasons why ophthalmologists have investigated the possibility of dropless cataract surgery. Dropless drug administration can be achieved using a variety of application methods, such as subconjunctival, subtenon, intracameral and intravitreous injections.…”

Section: Dropless Cataract Surgerymentioning

confidence: 99%

“…Suboptimal treatment with anti-inflammatory eye drops is also caused by incorrect instillation, particularly in the elderly cataract surgery population. 63,64 Homecare services are frequently involved to correctly instill the prescribed eye drops, which significantly increases the costs of postoperative care. In the subset of patients who adequately instill the prescribed eye drops, less than 3-5% of the instilled drug quantity reaches the aqueous humor.…”

Section: Dropless Cataract Surgerymentioning

confidence: 99%

“…In the subset of patients who adequately instill the prescribed eye drops, less than 3-5% of the instilled drug quantity reaches the aqueous humor. 63,65 Aqueous drug concentrations vary widely after topical drug administration. 66 A high drug concentration in the tear film is required to achieve adequate intraocular concentrations, which often leads to ocular side effects.…”

Section: Dropless Cataract Surgerymentioning

confidence: 99%

See 2 more Smart Citations

Prevention and treatment of cystoid macular edema after cataract surgery

Wielders

View full text Add to dashboard Cite

Material, Immunological, and Practical Perspectives on Eye Drop Formulation

Bennett

Chinnery

Downie

et al. 2020

Adv Funct Materials

View full text Add to dashboard Cite

Eye drops are the most common and inexpensive approach to topical ocular drug delivery. Eye drops offer a noninvasive treatment strategy; however, this can be detrimental to therapeutic efficacy when compared to invasive methods such as surgeries, implants, and injections. Improvements to the efficacy of the topical delivery of drugs to ocular tissues are currently being explored and much of this work centers on adjusting the formulation of the eye drops and prolonging the bioavailability of the therapeutic agent. This is often in preference to improving other patient‐focused or clinical factors. In this progress report, conventional, commercially available polymer eye drops are explored and the ability for current and future innovations to maintain the existing benefits of eye drops to the patient is assessed. The final materials and form of the drops (liquid, gel, or other) and the immunological implications for the user are explored. There is currently no consensus for how to most effectively improve the ocular retention and drug delivery capabilities of eye drops, but key issues are highlighted in the context of current methods under development, and potential questions and considerations for future innovations are raised.

show abstract

Topical drug delivery devices: A review

Cited by 74 publications

References 144 publications

Polysaccharides in Ocular Drug Delivery

Polysaccharides in Ocular Drug Delivery

Prevention and treatment of cystoid macular edema after cataract surgery

Material, Immunological, and Practical Perspectives on Eye Drop Formulation

Contact Info

Product

Resources

About